US2528281080
US2528281080
Dianthus Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±89.4% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).
Beta (Market Relation)
0.18x
DefensiveVolatility (5Y p.a.)
89.4% p.a.
5-Year HorizonMax Drawdown (5Y)
-95.7%
5-Year HorizonSharpe Ratio
-0.09
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +137.2% |
| 3 Years | 75.4% | -53.5% | 1.18 | +91.4% |
| 5 Years | 89.4% | -95.7% | -0.09 | -5.7% |
| 10 Years | 85.7% | -98.2% | -0.17 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (89.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.2% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
8 ISS Score: 8 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
6 ISS Score: 6 / 10
Short Ratio
15.00